Start Your Search
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
P3.01-29 - St.Iv Lung Adenocarcinoma Treated by First-Line EGFR–Tyrosine Kinase Inhibitors-Survival, EGFR Mutation, Histologic Subtype (ID 12268)
12:00 - 13:30 | Author(s): Grzegorz Czyżewicz
The aim of the study is to evaluate the correlation of survival, EGFR mutation and histologic subtype of stage IV lung sensitive mutant adenocarcinoma treated with first-line EGFR–tyrosine kinase inhibitors (EGFR-TKI).
We retrospectively analyzed the clinical outcomes of 60 consecutive patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R ) who received first-line erlotinib, gefitinib or afatinib therapy between October 2011 and September 2017. Histologic subtype was classified according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society pulmonary adenocarcinoma classification.4c3880bb027f159e801041b1021e88e8 Result
There were 60 patient enrolled, including 26 men, mean age 68.88 years (range: 49-89 ) and 34 women, mean age 65.68 years (range: 44-82).
The average survival in women was 14.1 months and in men it was 13.3 months.
Average survival in 28 patients were treated with Erlotinib was 14.51 months, in 18 patients treated with Gefitinib it was 12.79 months and in 14 patients treated with Afatinib it was 13.55 months.
In 30 patients with the mutations (exon 19 deletion), the mean survival was 14.56 months.
In the group of 26 patients with mutations (exon 21 L858R ), the mean survival was 12.68 months.
The mean survival in the group of patients with acinar adenocarcinoma was 15.49 months, and in solid adenocarcinoma - 4.8 months.
Currently, 21 patients are alive and remain in observation, 12 of them are treated and 39 patients died.
In the multidimensional linear regression analysis, smoking was a factor decreasing the survival at p = 0.12, male gender decreased the survival rate p = 0.04, and the type of cancer subtype increased the survival rate p = 0.04. Erlotinib influenced the increase in survival at p = 0.15
Mutation in (exon 19 deletion), histological subtype of tumor and Erlotinib treatment are factors significantly affecting the survival of patients with stage IV adenocarcinoma of the lung.The EGFR mutation frequency is higher in the acinar subtype than in other subtypes.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.